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The three principal struts of transplantation are 
organ preservation, immunosuppression, and 
tissue typing. Major pragmatic advances have 
been made possible by improved static preserva-
tion with the University of Wisconsin solution. 
The safe preservation limits for all organs, but 
particularly the liver, have been greatly in-
creased since 1987. The most important ingredi-
ents of the University of Wisconsin solution are 
thought to be the impermeants that prevent cell 
swelling. Two research directions are identifi-
able in the literature-one, eliminate unneeded 
constituents of the University of Wisconsin solu-
tion, and the other, increase the additives, which 
already number more than 10. 1 
The growth of transplantation during the last 
decade owes much to cyclosporine. The use of 
cyclosporine with steroids, to which other agents 
can be added in more or less elaborate cocktails, 
made possible the transplantation of cadaveric 
kidneys, livers, hearts, and other organs with an 
effectiveness scarcely dreamed of 10 years ago. 
Yet, the full profile of cyclosporine actions is 
incomplete.2 
A side from its immunosuppressive qualities, 
the spectrum of seemingly unrelated cyclospor-
ine activities is bewildering.2 Nephrotoxicity and 
hypertension are the best known and principal 
dose-limiting side effects. Metabolic, cosmetic, 
and neurotoxic side effects may also occur. Some 
symptoms may be so subtle that they are not 
mentioned unless specific iJl!.quiries are made. 
The foregoing side effects of cyclosporine and 
its desired inhibition of the immune system had 
not been thought to be interrelated by a common 
mechanism. This has been changed by clinical 
observations with another immunosuppressive 
agent called FK 506 (Fujisawa Corporation, Osa-
ka, Japan), which has a totally different structure 
than cyclosporine. FK 506 is a macrolide obtained 
from cultures of Streptomyces tsukubaensis. 
Like cyclosporine, it inhibits the activation of T 
lymphocytes, in part by depressing the produc-
tion and expression of multiple cytokines of which 
interleukin 2 and interferon gamma have been the 
most extensively studied. 3 The in vivo immuno-
suppressive qualities ofFK 506 have been studied 
in mice, rats, dogs, monkeys, baboons, and hu-
mans. 4 To date, there has been only one investiga-
tional new drug trial for FK 506, and this has 
taken place at the University of Pittsburgh. How-
ever, multicenter trials are scheduled to begin in 
the spring of1990 in Europe and in approximately 
one dozen American centers. So far, investiga-
tional new drug applications have not been devel-
oped for indications other than in transplanta-
tion. 
Extensive clinical trials with FK 506 were be-
gun in February 1989,5,6 first, for the rescue of 
patients who had intractable liver allograft rejec-
tion or toxic reactions under immunosuppres-
sion, which included cyclosporine," and subse-
quently as primary therapy. By February 1,1990, 
36 kidneys, 151 livers, and 14 hearts, lungs, or 
heart-lung grafts had been transplanted with an 
immunosuppression regimen of FK 506 and low-
dose steroids. All of the thoracic organ recipients 
and more than 90% of the liver recipients are 
alive. The kidney recipients, who represented an 
unusually complex and difficult collection of 
cases, have a graft survival rate of 80%, with a 
patient mortality rate of 3%.7 Overall, the low 
mortality, high graft survival, good graft function 
rates, and relative nondependence on steroids 
reflect a large and safe therapeutic window for 
FK506. 
The side effects of FK 506 tend to affect the 
same organ systems as cyclosporine, although 
frequently not to the same extent and sometimes 
not in the same direction. It may be less nephro-
toxic than cyclosporine, usually does not produce 
hypertension, reduces instead of increases serum 
cholesterol levels, and has little effect on serum 
uric acid levels. It does not cause gingival hyper-
plasia or coarsening of the facial features and, 
instead of hirsutism, there may be hair loss. The 
diabetogenic and neurotoxic effects ofFK 506 are 
similar to those of cyclosporine. Because FK 506 
usually does not elicit a biochemical red flag such 
as azotemia to warn of overdosage, minor signs of 
neurotoxicity such as tremors, tingling of the 
hands and feet, light sensitivity, insomnia, night-
mares, and mood changes have been useful to 
help guide dosage adjustments (T.E.S, J.J.F., 
Mark Porter, MD, unpublished data, 1990). 
In rats and dogs, FK 506 and cyclosporine have 
other effects that could have therapeutic signifi-
cance in humans. Both drugs cause augmentation 
of the regeneration response after partial hepa-
tectomy,7 and they prevent the hepatocyte atro-
phy and organelle disruption that occur after por-
tacaval shunt (T.E.S., Kendrick A. Porter, MD, 
Vincenzo Mazzaferro, MD, et ai, unpublished 
data, 1990). 
T he fact that two such chemically different 
drugs as FK 506 and cyclosporine appear to mod-
ulate the same physiological and immunologic 
parameters would be difficult to explain were it 
not for discoveries about their binding sites. The 
cyclosporine binding site is a cytosolic protein 
with a molecular weight of 17 0008 called "cyclo-
philin," which possesses petidyl-prolyl isomerase 
(PPIase) activity.9,10 Petidyl-prolyl isomerase is 
an enzyme discovered in mammalian tissuesll that 
catalyzes the slow cis-trans isomerization of pro-
line peptide bonds in oligopeptides and acceler-
ates rate-limiting steps in the folding of several 
proteins during their synthesis. By virtue of its 
isomerization of partner molecules, PPIase could 
modulate various intracellular signal transduc-
tion processes, contributing to the manifold phys-
iological effects enumerated previously. Petidyl-
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prolyl isomerase is widely distributed in many 
tissues, not just in lymphocytes. For example, 
cyclophilinlike receptors are in the photorecep-
tors of Drosophila. In mutant DrosophUa defi-
cient in cyclophilin, rhodopsin production is de-
fective. 12 This observation could establish a link 
with the neurotoxicity caused by PPIase-inhibit-
ingdrugs. 
It was thought at first that cyclophilin and 
PPIase were identical. 9.10 This hypothesis became 
untenable when the cytosolic binding site of FK 
506 (molecular weight, 11 800) was found to be 
distinct from cyclophilin, but to also possess 
PPIase activity. 13.14 Thus, cyclophilin and the FK 
506 binding site seem to be members of an emerg-
ing class of novel and ubiquitous cytoplasmic pro-
teins that regulate T-cell activation but also regu-
late other metabolic processes. 
FK 506 probably will have other applications 
than in transplantation. Dramatic remissions us-
ing FK 506 have already been observed in hemo-
lytic-uremic syndrome, steroid-resistant ne-
phrotic syndrome caused by focal segmental 
glomerulonephritis, psoriasis, and malignant 
pyoderma gangrenosum (unpublished data, 
1989). Because FK 506 augments hepatic repair 
and regeneration' (T.E.S., Kendrick A. Porter, 
MD, Vincenzo Mazzaferro, MD, et aI, unpub-
lished data, 1990), it may be especially valuable 
for patients who have chronic liver disease with or 
without an autoimmune origin. 
Other new agents to control rejection also are 
being tested clinically. Murine monoclonal anti-
bodies (OKT3 is the prototype) can be directed 
against the whole T-Iymphocyte population. Clin-
ical trials in France15 and the United States16 are 
in progress with anti-interleukin 2-receptor anti-
bodies, which have a more highly focused target. 
These preparations are immunosuppressive, but 
their inherent immunogenicity and inconve-
nience of administration may limit their useful-
ness. Anti-T lymphocytes have also been used as 
carriers of cytocidal immunotoxins. 17 
Tissue matching is important with intrafamilial 
transplantation, but controversy continues about 
the value of HLA matching for cadaveric trans-
plantation. The issue has become one of public 
policy because tissue matching is used for kidney 
distribution nationally. Because by law the Unit-
ed Network of Organ Sharing has been required 
to collect reports on the almost 20 000 cadaveric 
kidney transplantations performed in the United 
States since November 1987, an analysis of this 
material to resolve the dispute is eagerly awaited. 
At the International Transplantation Society 
meeting (August 1990), a principal topic for de-
bate will be the justifiability of making tissue 
matching the basis for kidney distribution. 
Recently, several elective partial liver trans-
plantations from live donors have been performed 
at the University of Chicago, including the much 
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publicized event in late 1989 of an elective partial 
liver transplantation from a healthy mother to 
her daughter born with biliary atresia. The skill 
and courage of the management teams were test-
ed by significant but not unexpected operative 
complications in the recipients. However, at last 
report, all donors and recipients were well. Earli-
er in 1989, the same procedure was performed in 
Australia, Brazil, France, and Japan, with vari-
able results. All observers agree thatliving donor 
liver transplantation should be attempted only by 
experienced transplantation teams and at centers 
with the most sophisticated ancillary resources. 
This study was supported by research grants from the Veter-
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